SEC Form 4 · accession 0000899243-18-020445
CONSTELLATION PHARMACEUTICALS INC · CNST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Precision Onco Ltd
10% Owner
Period of report
Jul 23, 2018
Accepted (ET)
Jul 23, 2018 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 23, 2018 | C | 317,921 | — | A | 317,921 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series F Preferred StockF1 | — | Jul 23, 2018 | C | 3,500,000 | D | — | — | Common Stock | 317,921 | 0 | D |
Explanation of responses
- F1On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.